5hon MSN
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At ...
Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...
Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Moderna in a research report issued to ...
Investopedia on MSN11d
Moderna Price Levels to Watch After Stock's 12% Surge on TuesdayModerna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...
Berenberg Bank analyst Harry Gillis maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $33.00.
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback